{
      "Rank": 24,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease."
      ],
      "ArmGroupInterventionName": [
            "Biological: Mesenchymal stromal cells"
      ],
      "ArmGroupLabel": [
            "MSC therapy for severe COVID-19 infection"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04445454"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The overall objective of the study is to evaluate the safety and efficacy of MSC therapy combined with best supportive care in hospitalized patients with COVID-19."
      ],
      "BriefTitle": [
            "Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection"
      ],
      "CentralContactEMail": [
            "yves.beguin@chuliege.be",
            "audrey.janssen@chuliege.be"
      ],
      "CentralContactName": [
            "Yves Beguin, MD,PhD",
            "Audrey Janssen"
      ],
      "CentralContactPhone": [
            "(0032)43667201",
            "(0032)43667470"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "September 30, 2024"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Coronavirus Infection"
      ],
      "ConditionAncestorId": [
            "D000020969",
            "D000010335",
            "D000003333",
            "D000030341",
            "D000012327",
            "D000014777"
      ],
      "ConditionAncestorTerm": [
            "Disease Attributes",
            "Pathologic Processes",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Virus Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC01",
            "BC08",
            "All",
            "BC23"
      ],
      "ConditionBrowseBranchName": [
            "Infections",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "All Conditions",
            "Symptoms and General Pathology"
      ],
      "ConditionBrowseLeafAsFound": [
            "Infection",
            "Infection",
            "Coronavirus Infection"
      ],
      "ConditionBrowseLeafId": [
            "M2562",
            "M9435",
            "M5520",
            "M19643",
            "M21853",
            "M5707",
            "M22838",
            "M16674",
            "M14301"
      ],
      "ConditionBrowseLeafName": [
            "COVID-19",
            "Infections",
            "Communicable Diseases",
            "Coronavirus Infections",
            "Disease Attributes",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "Virus Diseases",
            "RNA Virus Infections"
      ],
      "ConditionBrowseLeafRelevance": [
            "low",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000007239",
            "D000003141",
            "D000018352"
      ],
      "ConditionMeshTerm": [
            "Infections",
            "Communicable Diseases",
            "Coronavirus Infections"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [
            "This study is a monocentric prospective phase I/II clinical trial, aiming at evaluating the safety and efficacy of 3 intravenous administrations of BM-MSC in 20 patients with severe to critical COVID-19 pneumonia."
      ],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "This study is a monocentric prospective phase I/II clinical trial, aiming at evaluating the safety and efficacy of 3 intravenous administrations of BM-MSC in 20 patients with severe to critical COVID-19 pneumonia.\n\nAfter signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease.\n\nThe trial will be open for inclusion for 2 years after initiation. Each patient will be followed for 90 days after inclusion. The total study duration will thus be 2 years and 90 days."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "COVID-19 patients Inclusion criteria\n\nMale or female patients aged at least 18 years and up to 70 years\nDiagnosed with microbiologically or radiologically confirmed COVID-19 pneumonia as defined by:\nExtensive interstitial pneumonia on CT scan, consistent with viral pneumonia, within 10 days prior to randomization\nAnd either positive result of COVID-19 PCR test within 14 days prior to inclusion or positive result of SARS-CoV2 PCR or serology within 14 days after inclusion.\n\nRequiring oxygen administration (SpO2 \u2264 93% on room air):\n\nGroup A: in standard or intensive care unit requiring supplemental oxygen\nGroup B: in intensive care unit under mechanical ventilation administered through a tracheal tube, either:\nfor less than or equal to 7 days\nfor 7 to 14 days, with persisting high inflammation (ferritin > 2,000 \u00b5g/L; ferritin > 1,000 \u00b5g/L and rising; lymphocytes < 800 with CRP > 70 mg/L and rising or ferritin > 700 \u00b5g/L and rising or LDH > 300 UI/L or D-Dimers > 1000 ng/ml), not explained by superinfection. Rising = compared to previous 24H.\nWritten consent of the patient, or - if impossible (clinical condition precluding capacity to consent) - of his/her legal representative, or - if impossible - of an impartial witness such as a physician from a non-participating department or member of the Ethics Committee. Any consent obtained this way shall be documented and confirmed by way of normal consent procedures at the earliest opportunity when the patient has recovered\n\nExclusion criteria\n\nOngoing pregnancy. Women of childbearing potential (WOCBP, defined as a premenopausal female capable of becoming pregnant) should use an appropriate method of contraception (oral, injectable, or mechanical contraception; women whose partners have been vasectomized or have received or are utilizing mechanical contraceptive devices).\nExtracorporeal membrane oxygenation\nLimitations to intensity of care\nLife expectancy < 24 hours\nKnown allergy to IMP component\nActive secondary infection\nAny malignancy (except non-melanoma skin carcinoma) within 2 years before inclusion\nPre-existing thrombo-embolic pathology\nSigns of an active drug or alcohol dependence, serious current illness, mental illness or any factors which, in the opinion of the Investigator, may interfere with subject's ability to understand and comply with study requirements\nPatients with any serious medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the patient's safe participation in and completion of the study.\nParticipation in another clinical trial(use of anti-viral/supportive drugs for COVID-19 infection on a compassionate use basis is not an exclusion criterion).\n\nMSC donors Inclusion criteria\n\nUnrelated to the patient\nMale or female\nAge > 18 yrs\nNo HLA matching required\nFulfills generally accepted criteria for allogeneic HSC donation\nInformed consent given by donor\n\nExclusion criteria\n\nAny condition not fulfilling inclusion criteria\nKnown allergy to lidocaine\nAny risk factor for transmissible infectious diseases, in particular HIV"
      ],
      "EnrollmentCount": [
            "20"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "MSC therapy for severe COVID-19 infection"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Li\u00e8ge as described in IMPD and its SOPs."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal stromal cells"
      ],
      "InterventionOtherName": [
            "MSC"
      ],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "mesenchymal stromal cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "September 21, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "September 19, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "University of Liege"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Li\u00e8ge"
      ],
      "LocationContactEMail": [
            "yves.beguin@chuliege.be"
      ],
      "LocationContactName": [
            "Yves Beguin, MD,PhD",
            "Benoit Misset, MD,PhD",
            "Nathalie Layios, MD",
            "Bernard Lambermont, MD,PhD",
            "Michel Moutschen, MD,PhD",
            "Gilles Darcis, MD,PhD"
      ],
      "LocationContactPhone": [
            "(0032)43667201"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator"
      ],
      "LocationCountry": [
            "Belgium"
      ],
      "LocationFacility": [
            "CHU de Li\u00e8ge"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "4000"
      ],
      "MaximumAge": [
            "70 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "University of Liege"
      ],
      "OrgStudyId": [
            "TJT2012"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [
            "To determine the FACS analysis of regulatory T-cell (Treg) levels and Treg and Tconv sub-populations",
            "To assess the cytotoxic activity by MLR"
      ],
      "OtherOutcomeMeasure": [
            "To investigate immune modulation",
            "To compare the cytotoxic activity of PBMCs from healthy control and COVID-19 patients (divided in responders / non-responders to MSC therapy) against MSCs in vitro"
      ],
      "OtherOutcomeTimeFrame": [
            "Day 28",
            "Day 28"
      ],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "CHU de Li\u00e8ge"
      ],
      "OverallOfficialName": [
            "Yves Beguin, MD,PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "September 30, 2024"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "To assess the infusional toxicity",
            "To assess the number of Adverse events of special interest : Incidence of infections (bacterial, viral, fungal, parasitic) and thrombo-embolic events.",
            "Group A (patients not under mechanical ventilation): to determine the pourcentage of patients requiring mechanical ventilation",
            "Group B (patients under mechanical ventilation): to determine the vital status (dead/alive)"
      ],
      "PrimaryOutcomeMeasure": [
            "To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia",
            "To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia",
            "To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia",
            "To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Day 28",
            "Day 28",
            "Day 28",
            "Day 28"
      ],
      "ReferenceCitation": [
            "Gr\u00e9goire C, Layios N, Lambermont B, Lechanteur C, Briquet A, Bettonville V, Baudoux E, Thys M, Dardenne N, Misset B, Beguin Y. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Front Immunol. 2022 Jul 4;13:932360. doi: 10.3389/fimmu.2022.932360. eCollection 2022."
      ],
      "ReferencePMID": [
            "35860245"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "University of Liege"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Yves Beguin"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "MD,PhD"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "To assess the clinical status (on a 7-point WHO ordinal scale)",
            "To assess the duration of oxygen therapy and/or mechanical ventilation",
            "To assess the length of stay at the intensive care unit and of hospitalization",
            "To assess the number of organ failures",
            "To assess the intensity of the inflammatory response",
            "To assess the evolution of coagulation parameter",
            "To assess the presence of Biomarker of lung lesion, repair and scarring",
            "To assess the v iral load over the 28 days after inclusion and seroconversion to COVID-19 over the 90 days after inclusion",
            "To assess the pulmonary function",
            "To assess the number of adverse reactions (ARs), ARs grade > 3, serious adverse events (SAEs), serious ARs (SARs), suspected expected and unexpected SARs (SESARs and SUSARs)."
      ],
      "SecondaryOutcomeMeasure": [
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Day 28",
            "Day 28",
            "Day 90",
            "Day 28",
            "Day 28",
            "Day 28",
            "Day 28",
            "Day 90",
            "Day 90",
            "Day 90"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "June 12, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "September 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 24, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "June 19, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "June 22, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}